AR062726A1 - Composiciones que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Composiciones que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
AR062726A1
AR062726A1 ARP070103993A ARP070103993A AR062726A1 AR 062726 A1 AR062726 A1 AR 062726A1 AR P070103993 A ARP070103993 A AR P070103993A AR P070103993 A ARP070103993 A AR P070103993A AR 062726 A1 AR062726 A1 AR 062726A1
Authority
AR
Argentina
Prior art keywords
anion
heteroaryl
aryl
alkyl
group
Prior art date
Application number
ARP070103993A
Other languages
English (en)
Spanish (es)
Inventor
Detief Sulzle
Thomas Brumby
Lutz Lehmann
Timo Stellfeld
Ananth Srinivasan
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR062726A1 publication Critical patent/AR062726A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP070103993A 2006-09-08 2007-09-10 Composiciones que comprenden compuestos marcados con 18f y metodos relacionados AR062726A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
AR062726A1 true AR062726A1 (es) 2008-11-26

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103993A AR062726A1 (es) 2006-09-08 2007-09-10 Composiciones que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2289564A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2662449A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289564A3 (en) 2006-09-08 2012-11-14 Piramal Imaging SA Derivatives of aniline as precursors for F18-labeling
MX2009009291A (es) * 2007-03-01 2009-12-14 Bayer Schering Pharma Ag Compuestos activos biologicamente marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo.
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
JP2014526952A (ja) * 2011-06-09 2014-10-09 ジーイー・ヘルスケア・リミテッド 蒸留装置及び方法
DK3560937T3 (da) * 2013-03-15 2023-02-13 Cancer Targeted Tech Llc Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
AR112756A1 (es) 2017-07-11 2019-12-11 Synthorx Inc Incorporación de nucleótidos no naturales, y su método
MX2020001336A (es) 2017-08-03 2020-08-20 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades autoinmunes.
JP2021522196A (ja) * 2018-04-20 2021-08-30 ザ ジェネラル ホスピタル コーポレイション 血液脳関門を越えて送達するためのアセチル化プロドラッグ
JP7702872B2 (ja) 2019-02-06 2025-07-04 シンソークス, インコーポレイテッド Il-2コンジュゲートおよびその使用方法
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
KR20250164815A (ko) 2023-03-31 2025-11-25 닛산 가가쿠 가부시키가이샤 피라졸 화합물 및 유해 생물 방제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1989002897A1 (en) 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
MC2144A1 (fr) * 1988-10-14 1992-02-19 Univ Tulane Peptides therapeutiques
DE69023500D1 (de) * 1989-06-02 1995-12-14 Univ Georgetown Verfahren zum nachweis von antikörpern gegen streptokinase.
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
EE200000386A (et) 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US7115766B2 (en) 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
WO2003087069A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
JP4563806B2 (ja) * 2002-08-09 2010-10-13 アステラス ファルマ ユーロープ ベスローテン フェンノートシャップ P−セレクチンに対する結合性化合物
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
EP1597270A2 (en) 2003-02-20 2005-11-23 University of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
EP1912634A4 (en) 2005-07-29 2010-06-09 Bayer Healthcare Llc PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
EP2289564A3 (en) 2006-09-08 2012-11-14 Piramal Imaging SA Derivatives of aniline as precursors for F18-labeling

Also Published As

Publication number Publication date
IL211033A0 (en) 2011-04-28
CA2662449A1 (en) 2008-03-13
CR10654A (es) 2009-04-14
EP2289564A2 (en) 2011-03-02
CA2858907A1 (en) 2008-03-13
EP2279759A3 (en) 2013-04-17
KR20090058553A (ko) 2009-06-09
JP5722966B2 (ja) 2015-05-27
TN2009000063A1 (en) 2010-08-19
PE20080850A1 (es) 2008-09-02
JP2010503618A (ja) 2010-02-04
AU2007294124A1 (en) 2008-03-13
EP2063918B1 (en) 2014-02-26
EP2289564A3 (en) 2012-11-14
NO20091428L (no) 2009-06-03
IL211526A0 (en) 2011-05-31
JP5603074B2 (ja) 2014-10-08
CL2007002620A1 (es) 2008-05-30
JP2014028813A (ja) 2014-02-13
US20080292548A1 (en) 2008-11-27
EP2455105A2 (en) 2012-05-23
IL211527A0 (en) 2011-05-31
IL197363A0 (en) 2011-08-01
EP3056509A1 (en) 2016-08-17
CO6150196A2 (es) 2010-04-20
EP2279759A2 (en) 2011-02-02
WO2008028688A3 (en) 2008-11-13
MX2009002492A (es) 2009-08-28
MA30780B1 (fr) 2009-10-01
BRPI0716554A2 (pt) 2013-09-24
EP2455105A3 (en) 2012-09-05
TW200829277A (en) 2008-07-16
EP2455105B1 (en) 2016-02-17
US8557776B2 (en) 2013-10-15
RU2009112716A (ru) 2010-10-20
EP2063918A2 (en) 2009-06-03
WO2008028688A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
AR062726A1 (es) Composiciones que comprenden compuestos marcados con 18f y metodos relacionados
CO6220836A2 (es) Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoilo
Wang et al. Chloride ion-catalyzed generation of difluorocarbene for efficient preparation of gem-difluorinated cyclopropenes and cyclopropanes
Kang et al. Copper-catalyzed trifluoromethylthiolation of aryl and vinyl boronic acids with a shelf-stable electrophilic trifluoromethylthiolating reagent
AR073892A1 (es) Proceso de preparacion de inhibidores de sglt
HRP20191249T1 (hr) Procesi za pripremu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina
BR102013003576A2 (pt) Métodos de produzir compostos de sulfilimina
RU2580915C2 (ru) Пламегасящая композиция, содержащая органическую кислоту
IL264541A (en) History of sulfamolepyrolamide and their use as drugs for the treatment of jaundice b
ES2543588T3 (es) Derivados de 2-(2-hidroxibifenil-3-il)-1H-benzoimidazol-5-carboxamidina como inhibidores del factor VIIa
IL284528B2 (en) Liquid concentrate fire retardant compositions containing mixtures of ammonium phosphates
RU2015148006A (ru) Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
ME02295B (me) Inhibitori neprilizina
AR074705A1 (es) Procedimiento de preparacion de benzociclobutenos funcionalizados, intermediarios y aplicacion en la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
AR049401A1 (es) Aza-biciclononanos
KR20040078078A (ko) 강화액소화약제의 조성물
AR054088A1 (es) Triazoles como inhibidores de proteinquinasas. composiciones farmaceuticas
AR071592A1 (es) Fenoxibenzamidas sustituidas
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
Nurminen et al. Mechanisms of the substitution reactions of phosphoramidites and their congeners
PE20090956A1 (es) PROCESO PARA LA OBTENCION DE DERIVADOS DE PIRIDO [2,1-a] - ISOQUINOLINA
Liu et al. Efficient synthesis of unsymmetrical S-(bromodifluoromethyl) diarylsulfonium salts for electrophilic bromodifluoromethylating reagents
Maciejewski et al. Synthetic Methods for Preparing Ionic Liquids Containing Hypophosphite and Carbon-Extended Dicyanamide Anions.
CN108478980A (zh) 一种泡沫灭火剂

Legal Events

Date Code Title Description
FB Suspension of granting procedure